

HOUSE AMENDMENTS TO HOUSE BILL 3817

By COMMITTEE ON BEHAVIORAL HEALTH AND HEALTH CARE

April 16

1 On page 1 of the printed bill, line 2, delete “; creating new provisions; and amending ORS
2 475.005”.

3 Delete lines 4 through 26 and delete pages 2 through 6 and insert:

4 **“SECTION 1. (1) As used in this section, ‘ibogaine’ means a naturally occurring indole
5 alkaloid extracted from the root bark of the Tabernanthe iboga shrub.**

6 **“(2) The Oregon Health Authority and the Department of Veterans’ Affairs shall study
7 the consumption of ibogaine by individuals who have post-traumatic stress disorder, major
8 depressive disorder, an anxiety disorder or substance use disorder for the purpose of treating
9 the disorder. The authority and the department shall submit a report in the manner provided
10 by ORS 192.245, and may include recommendations for legislation, to the interim committees
11 of the Legislative Assembly related to health care no later than September 15, 2029. The re-
12 port must include information about and recommendations on the following:**

13 **“(a) The available medical, psychological and scientific studies, research and other data
14 relating to the safety and efficacy of ibogaine;**

15 **“(b) The sourcing and production of ibogaine;**

16 **“(c) Recommended doses and delivery methods of ibogaine;**

17 **“(d) Testing and safety of ibogaine products;**

18 **“(e) Best practices for client and public health and safety, including client data protection
19 and client consent;**

20 **“(f) Training and requirements for individuals who administer ibogaine to clients;**

21 **“(g) Requirements for how ibogaine is administered to clients and how clients are pre-
22 pared and supported through the duration of and after administration;**

23 **“(h) Requirements for a system to track ibogaine and locations at which ibogaine will be
24 produced, stored and administered or consumed;**

25 **“(i) Client screening and eligibility requirements for consumption of ibogaine, and any
26 conditions that would cause a client to be ineligible;**

27 **“(j) Funding mechanisms for the administration of an ibogaine program and the long-
28 term sustainability of the program; and**

29 **“(k) Reporting of data on ibogaine consumption and client outcomes.**

30 **“SECTION 2. Section 1 of this 2025 Act is repealed on January 2, 2030.”.**